Exosome Companies Prospering in this Uncertain Market

Published: October 2023

Exploitation of exosomes for various research purposes and their utility in disease detection and pathologies has gained momentum in the recent years. We analyzed over 40 exosome companies and over 20 non-industry players that are engaged in the development of exosome based therapies. In this article, discover 5 exosome therapy developers and their capabilities in this industry.

In recent years, exosomes have garnered significant interest from researchers, as well as industry players, owing to their potential in diagnosis and treatment of various diseases. Exosomes are extracellular vesicles, which have endosomal origin and may contain different biomolecules, including proteins, DNA, lipids, miRNA or RNA, based on the type of cell of their origin and its conditions. Exosomes are known to have some unique functions that make them alter recipient cell bioactivities and act like intercellular messengers. Over time, advancements in the field of nanotechnology have paved the way for the development of exosome therapeutics. The growing interest in using exosomes for therapeutic purposes can be attributed to their ability to easily enter the respective organs, show best results even in a weakened immune system and be stored for longer periods of time, owing to their greater life span.

Owing to various advantages offered by exosomes, including low immunogenicity, high targeting ability, enhanced circulating ability and ability to cross blood-brain-barrier, exosomes have gained significant popularity. Various researchers and industry players have undertaken several initiatives to explore the potential of exosomes for diagnosis and treatment of various diseases. Moreover, advanced exosome technologies are being developed to fully substructure the therapeutic applications of exosomes and extensive research is being conducted to develop methods for extraction of exosomes with high level of purity and sensitivity. Close to 130 exosome therapeutics, intended for the treatment of multiple indications, are being developed and investigated by various industry and non-industry players. However, as of current market, no drug is approved till date, some of the molecules have entered the advance stage of clinical phases. With the rise in research activity, exosome companies have received grants of over USD 200 million and received over USD 550 million by key investors. The activity is not limited to raising funds, the developers have also joined hands for multiple purposes and signed 50+ deals.

Roots Analysis has conducted an exhaustive study on Exosome Therapy Market featuring the current market landscape and future opportunity for the companies / organizations involved in exosome industry, over a span of 18 years.

Despite several advancements, there are various challenges in development of exosomes, for which stakeholders are leveraging the expertise of various contract service providers offering exosome development and manufacturing services. These service providers are actively upgrading their capabilities and infrastructure to accommodate the demand for these extracellular vesicles. Driven by the growing research efforts, development of advanced methods for isolation and purification of exosomes, and efforts of various stakeholders, this segment of industry is likely to witness noteworthy market growth in the foreseen future.

Table of Contents

Below, we have listed (in alphabetical order), the top 5 exosome companies actively developing exosome based therapeutics. 
1. Aegle Therapeutics
2. Coya Therapeutics
3. Evox Therapeutics
4. Nano 24 ((earlier known as OBCTCD24)
5. ReNeuron

Top 5 Exosome Companies

Interested in exploring all 60+ Exosome Companies developing therapeutics and their recent initiatives?

Discover Below the Details on Top 5 Exosome Companies Developing Therapeutics

Let us deep dive to understand the current status of drugs being developed by top 5 developers (shortlisted on the basis of stage of development of drugs or amount of funding received) in the exosome therapy market.

Aegle Therapeutics, Evaluating Mesenchymal Stem Cell Derived Exosome Therapy in Phase I/II Clinical Trial

1. Aegle Therapeutics

Company Overview

Aegle Therapeutics is a clinical stage biotechnology company focused on the development of exosomes therapeutics by utilizing its isolation technology. It focuses on developing a pipeline of exosomes secreted by allogeneic bone marrow derived mesenchymal stem cells. It is worth mentioning that the company employs its platform for isolating exosomes, while preserving their structural and functional integrity to develop impactful therapeutics.

Aegle Therapeutics: Company Snapshot

Particulars                               Specifications
Company Logo Aegle-Therapeutics-exosome
Year of Establishment 2013
Number of Employees 2-10
Headquarters Aegle-Therapeutics-Headquarters

Exosome Drugs Pipeline

Aegle Therapeutic’s lead drug, AGLE-102 is in phase I/IIa (NCT05078385) clinical trials for treatment of severe second-degree burns. The company announced dosing of the first patient in August 2023 at the study centers in the US. Another phase I/II (NCT04173650) clinical trial evaluating AGLE-102 for Epidermolysis Bullosa is planned to begin in October 2023.1

Funding Received by Aegle Therapeutics: ~$11 Million 

  1. In September 2020, Aegle Therapeutics raised Venture Series A worth USD 6.5 million for AGLE-102 development and clinical studies.
  2. In January 2020, Aegle Therapeutics raised Venture Funding worth USD 4 million for AGLE-102 development and its clinical studies.

Further details on exosome therapies developed by Aegle Therapeutics as well as details on its clinical trials and funding have been provided in detail in the report.

Coya Therapeutics, Developing Biologics and Exosome Therapy for Treg Modulation

2. Coya Therapeutics

Company Overview

Coya Therapeutics is a US based company, focused on the research and development of novel therapeutics for ALS and other neurodegenerative disorders. Coya Therapeutics focuses on the development of Treg Therapy. The company has more than five molecules, including biologics and exosomes, in its pipeline for the treatment of various indications.

Coya Therapeutics: Company Snapshot

Particulars                               Specifications
Company Logo Coya-Therapeutics-exosome
Year of Establishment 2020
Number of Employees 2-10
Headquarters Coya-Therapeutics-Headquarters

Exosome Drugs Pipeline:

The company currently has a preclinical stage allogeneic Treg derived exosome candidate, COYA 201. Under development in collaboration with Houston Methodist, Coya Therapeutics aims to complete the animal model studies soon. Another candidate COYA 206 is in discovery in collaboration with Carnegie Mellon University.2

Funding Received by Coya Therapeutics: 

  1. In June 2022, Coya Therapeutics raised $10.3 million via Venture Series A to spend it on the clinical trials of exosome-based therapies.

Recent Developments: 

  1. In June 2022, Coya Therapeutics entered into a technology licensing agreement with Carnegie Mellon University for enabling exosome engineering technology.
  2. In February 2021, the company acquired Nicoya for approximately USD 10 billion.

Further details on exosome therapies developed by Coya Therapeutics as well as details on its clinical trials, funding and partnerships have been provided in detail in the report

Evox Therapeutics, with Focus on Engineered Exosomes, is Expanding its IP Estate With the Addition of engEx-AAV™ technology

3. Evox Therapeutics

Company Overview

Evox Therapeutics is a biotechnology company focused on engineering the extracellular vesicles’ natural trafficking abilities to develop effective therapeutics. It is focused on developing the novel exosome-based therapeutics for the treatment of severe as well as rare diseases.

Evox Therapeutics: Company Snapshot

Particulars                               Specifications
Company Logo https://www.rootsanalysis.com/dashboard/uploads/create_links/Evox-Therapeutics-Headquarters.webp
Year of Establishment 2016
Number of Employees 11-50
Headquarters Skyports - Headquarters

Exosome Drugs Pipeline

The company currently has an AAV vector encoding the phenylalanine hydroxylase (PAH) enzyme delivered using exosomes in preclinical development for treatment of adult and pediatric phenylketonuria. Another exosome therapy in preclinical is targeting cardiovascular disorders.  

Funding Received by Evox Therapeutics: ~$151 Million 

  1. In February 2021, Evox Therapeutics raised $95 million in the Venture Series C round from key investors Redmile Group, OrbiMed, Invus, Oxford Sciences Innovation (OSI), GV, Cowen Healthcare Investments, Eli Lily for the purpose of advancing its exosome-based pipeline to clinical scale.
  2. In June 2020, Evox Therapeutics raised €8.8 million to develop exosome-based therapeutics for neurological disorders. 

Recent Developments: 

  1. In July 2023, the company acquired engEx-AAV™ technology from Codiak Biosciences. The technology allows loading and targeted release of AAV in to and from the exosomes.3
  2. In November 2020, Evox Therapeutics entered into a research and development agreement with University of Oxford to develop exosome-based therapies for rare disorders.
  3. In June 2020, Evox Therapeutics received a $20 million upfront payment from Eli Lilly to explore exosome technology.
  4. In April 2020, Evox Therapeutics signed a Product Development and Commercialization Agreement for exosomes development with CEVEC Pharmaceuticals.

Further details on exosome therapies developed by Evox Therapeutics as well as details on its clinical trials, funding and partnership have been provided in detail in the report.

Nano24, is Developing the Next Generation of Immunomodulators Using Exosome Technology

4. Nano 24 (earlier known as OBCTCD24)

Company Overview

Nano 24 is a clinical stage biopharmaceutical company focused on the development of CD24-based therapeutics delivered by exosomes. The company aims to achieve excellence in the field of translational medicine by developing innovative CD24-based therapies focused on a broad range of disease areas, including ARDS, respiratory and autoimmune diseases, with the highest possible safety and quality standards. 

Nano24: Company Snapshot

Particulars                               Specifications
Company Logo Nano-24-exosome
Year of Establishment 2020
Number of Employees 2-10
Headquarters Nano-24-Headquarters

Exosome Drugs Pipeline

EXO-CD24, a new generation of immunomodulators is developed using two breakthrough technologies- exosomes act as carrier for the drug CD24, which is a novel innate checkpoint inhibitor. EXO-CD24 can be used for multiple indications, primarily for the treatment of acute respiratory distress syndrome (ARDS). There is an active (status unknown) phase II trial in Israel evaluating the safety profile and efficacy of the drug (CD 24) in patients with moderate or severe COVID-19.4

Further details on exosome therapies developed by Nano24 as well as details on its clinical trials have been provided in detail in the report.

CustomExTM, a Technology Platform Developed by ReNeuron is Offering Customizable Exosomes as a Targeted Delivery Platform for Complex Drug Modalities

5. ReNeuron

Company Overview

ReNeuron is a UK based exosome technology company focused on the development of stem cell-based therapeutics. It is developing a monotherapy based on exosomes, for the treatment of Ophthalmic Diseases. The derived source of this drug is Mesenchymal Stem Cells, which can be administered via subretinal route. 

ReNeuron: Company Snapshot

Particulars                               Specifications
Company Logo ReNeuron-exosome
Year of Establishment 1997
Number of Employees 11-50
Headquarters Skyports - Headquarters

Exosome Drugs Pipeline

In September 2023, ReNeuron announced successful in vivo studies for its CustomEX™ stem cell derived exosome technology platform. 

Funding Received by ReNeuron: ~$0.3 Million 

  1. In August 2019, ReNeuron received grant worth $0.29 million by University of Cardiff for development of drugs to treat neurological disorders.5

Recent Developments:

  1. In July 2022, ReNeuron entered into a technology licensing and supply agreement with Fosun Pharma for the expansion of its cell therapy portfolio.
  2. In January 2022, ReNeuron signed a technology licensing agreement with Fosun Pharma for the technology transfer focusing on developing drugs for genetic disorders.
  3. In December 2021, ReNeuron entered into a research and development agreement with UCL (University College London) for the development of cancer therapies.

Further details on exosome therapies developed by ReNeuron as well as details on its clinical trials, funding and partnership have been provided in detail in the report.

What about the other Exosome Companies Developing Drugs Around the World?

The above presentation features five Exosome Therapy Developers selected from a pool of close to 65 exosome companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com

About Author

Nancy Kapila

I am Nancy Kapila, an accomplished pharmaceutical consultant with a rich and diverse experience spanning more than 5 years. My educational background includes a Master's degree in Pharmaceutics (M.Pharm) from Panjab University, which has provided me with a solid foundation in understanding the intricate mechanisms of drugs and their interactions within the human body. Throughout my professional journey, I have had the privilege of working with various pharmaceutical companies, leveraging my expertise to provide valuable insights and strategic guidance. 

What sets me apart is my unwavering commitment to staying at the forefront of the ever-evolving pharmaceutical landscape. In an industry characterized by rapid advancements and dynamic changes, I make it a priority to remain well-informed about the latest developments, regulatory updates, and emerging trends. This continuous learning not only keeps me well-equipped to navigate the complexities of the field but also enables me to offer innovative solutions that drive client success. I am deeply fascinated by the potential of data analytics and its transformative impact on decision-making. By delving into data, I can identify patterns, trends, and opportunities that might otherwise remain hidden. This enables me to provide clients with evidence-based recommendations that optimize processes, enhance product development, and drive operational efficiency
My journey has been marked by a continuous quest for knowledge, an unrelenting passion for data-driven insights, and an unwavering commitment to guiding pharmaceutical companies towards success in an ever-changing world.

Email: Nancy.Kapila@rootsanalysis.com
LinkedIn: https://www.linkedin.com/in/nancy-kapila-4336b4129/

Source: https://clinicaltrials.gov/study/NCT04173650?term=agle-102&rank=2
Source: https://www.labmate-online.com/news/news-and-views/5/evox-therapeutics/evox-therapeutics-completes-acquisition-of-exosome-aav-technology-and-intellectual-property/60704
Source: https://clinicaltrials.gov/study/NCT04969172
Source: https://www.reneuron.com/wp-content/uploads/RENE-RD-Update-04.09.23.pdf


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry